SUBSCRIBE
SUBSCRIBE

ALS

Pictured: Sanofi Distribution Center
Drug Development
Sanofi, Denali ALS Candidate Flops in Mid-Stage Trial
In a Phase II study, Sanofi and Denali’s RIPK1 inhibitor SAR443820/DNL788 failed to meet the primary endpoint of improved functional performance in amyotrophic lateral sclerosis patients.
February 19, 2024
 · 
2 min read
 · 
Tristan Manalac
Load More
PRESS RELEASES
Press Releases
FNIH Names Recipients of the 2026 Charles A. Sanders, MD, Partnership Award
June 4, 2026
 · 
3 min read
Press Releases
LeonaBio Presents on ATH-1105 at 5th Annual ALS Drug Development Summit
June 4, 2026
 · 
7 min read
Press Releases
EverythingALS and Vision 2030 Invest in Allen Institute Initiative to Accelerate ALS Research
June 3, 2026
 · 
6 min read
Press Releases
Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
June 2, 2026
 · 
4 min read
Press Releases
Coya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit
May 27, 2026
 · 
4 min read
Press Releases
AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS
May 22, 2026
 · 
5 min read
Press Releases
OutSee Selected for Discovery Award from Longitude Prize on ALS to Accelerate AI-Based Target Discovery
May 19, 2026
 · 
3 min read
Press Releases
NeuroVision Acquires Durin Life Sciences to Advance Earlier Detection and Management of Neurodegenerative Disease
May 12, 2026
 · 
2 min read
Press Releases
Coya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
May 12, 2026
 · 
10 min read
Press Releases
Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
May 12, 2026
 · 
4 min read
Press Releases
The ALS Association Awards $3 Million to Bring Expert ALS Care to Communities that Don’t Have It
May 8, 2026
 · 
7 min read
Press Releases
Clene to Present at Upcoming May 2026 Conferences
May 5, 2026
 · 
1 min read
Press Releases
After Successful FDA Meeting, Clene Filing Accelerated Approval NDA for ALS
May 4, 2026
 · 
7 min read
Press Releases
Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis
May 1, 2026
 · 
6 min read
Press Releases
La Jolla Labs, Inc. Announces First Patient Treated with Custom Antisense Therapy GBFsen for familial ALS
April 30, 2026
 · 
1 min read
Press Releases
CIRM Awards AcuraStem $7.5 Million in Grant Funding to Advance AS-241 Toward a First-in-Human Trial for ALS and FTD
April 29, 2026
 · 
3 min read
Press Releases
VectorY Therapeutics Receives U.K. MHRA Authorization and EMA Approval to Initiate Phase 1/2 PIONEER-ALS Clinical Trial of VTx-002 in People Living with Amyotrophic Lateral Sclerosis (ALS)
April 28, 2026
 · 
3 min read
Press Releases
Ractigen Therapeutics Presents Positive Phase I Data for RAG-17 in SOD1-ALS at the 2026 AAN Annual Meeting, Demonstrating 81% Reduction in Neurofilament Light Chain
April 22, 2026
 · 
6 min read
Press Releases
AB Science: New publication on medrxiv demonstrating substantial survival benefits and preserved quality of life with masitinib in ALS patients
April 21, 2026
 · 
9 min read
Press Releases
AB Science provides an update on its clinical development program.
April 17, 2026
 · 
10 min read
Load More